AU2003248893A1 - Compositions and methods for the treatment of parkinson's disease and tardive dyskinesias - Google Patents

Compositions and methods for the treatment of parkinson's disease and tardive dyskinesias

Info

Publication number
AU2003248893A1
AU2003248893A1 AU2003248893A AU2003248893A AU2003248893A1 AU 2003248893 A1 AU2003248893 A1 AU 2003248893A1 AU 2003248893 A AU2003248893 A AU 2003248893A AU 2003248893 A AU2003248893 A AU 2003248893A AU 2003248893 A1 AU2003248893 A1 AU 2003248893A1
Authority
AU
Australia
Prior art keywords
parkinson
disease
compositions
treatment
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003248893A
Other versions
AU2003248893A8 (en
Inventor
Jodi Nelson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alpha Research Group LLC
Original Assignee
Alpha Research Group LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/192,414 external-priority patent/US20020198231A1/en
Application filed by Alpha Research Group LLC filed Critical Alpha Research Group LLC
Publication of AU2003248893A1 publication Critical patent/AU2003248893A1/en
Publication of AU2003248893A8 publication Critical patent/AU2003248893A8/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
AU2003248893A 2002-07-09 2003-07-09 Compositions and methods for the treatment of parkinson's disease and tardive dyskinesias Abandoned AU2003248893A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US10/192,414 2002-07-09
US10/192,414 US20020198231A1 (en) 1999-07-13 2002-07-09 Compositions and methods for the treatment of Parkinson's disease
US47974803P 2003-06-19 2003-06-19
US60/479,748 2003-06-19
PCT/US2003/021463 WO2004004660A2 (en) 2002-07-09 2003-07-09 Compositions and methods for the treatment of parkinson’s disease and tardive dyskinesias

Publications (2)

Publication Number Publication Date
AU2003248893A1 true AU2003248893A1 (en) 2004-01-23
AU2003248893A8 AU2003248893A8 (en) 2004-01-23

Family

ID=30117814

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003248893A Abandoned AU2003248893A1 (en) 2002-07-09 2003-07-09 Compositions and methods for the treatment of parkinson's disease and tardive dyskinesias

Country Status (5)

Country Link
EP (1) EP1581167A4 (en)
JP (1) JP2006514917A (en)
AU (1) AU2003248893A1 (en)
CA (1) CA2531810A1 (en)
WO (1) WO2004004660A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8551986B2 (en) 2005-12-08 2013-10-08 The Mclean Hospital Corporation Treatment of sequelae of psychiatric disorders
EP1983988A2 (en) * 2006-02-16 2008-10-29 The McLean Hospital Corporation Methods and compositions for the treatment of parkinson's disease
EP2437744B1 (en) 2009-06-03 2015-06-03 Marquette University Modulation of kcnq potassium channel activity for treatment of psychiatric disorders and the symptoms thereof
AU2010329847A1 (en) 2009-12-11 2012-07-26 Genecode As Methods of facilitating neural cell survival using GDNF family ligand (GFL) mimetics or RET signaling pathway activators
CN113354581B (en) * 2020-03-06 2023-06-20 华南理工大学 Preparation method and application of chiral chloroquine and phosphate thereof
CN113527201A (en) * 2020-04-14 2021-10-22 瀚海新拓(杭州)生物医药有限公司 Optically active chloroquine and hydroxychloroquine and analogs thereof, preparation method, composition and application thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5430039A (en) * 1990-09-28 1995-07-04 Cephalon, Inc. Treatment of neurological disorders
US5496836A (en) * 1994-05-05 1996-03-05 Mount Sinai School Of Medicine Of The City University Of New York Use of famotidine and related compounds in the treatment of movement disorders
DE4428199A1 (en) * 1994-08-09 1996-02-15 Univ Ludwigs Albert Use of flunitrazepam and/or chloroquine
WO2001003649A2 (en) * 1999-07-13 2001-01-18 Alpha Research Group, Llc Compositions and methods for the treatment of parkinson's disease

Also Published As

Publication number Publication date
JP2006514917A (en) 2006-05-18
CA2531810A1 (en) 2004-01-15
AU2003248893A8 (en) 2004-01-23
EP1581167A4 (en) 2008-10-29
WO2004004660A2 (en) 2004-01-15
WO2004004660A3 (en) 2005-11-03
EP1581167A2 (en) 2005-10-05

Similar Documents

Publication Publication Date Title
AU2003223579A1 (en) Combinations of cox-2 inhibitors and other agents for the treatment of parkinson's disease
WO2004030615A8 (en) Compositions and methods for the diagnosis and treatment of tumor
EP1571968A3 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2004016225A8 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2004045516A9 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2003072035A8 (en) Compositions and methods for the treatment of immune related diseases
WO2004041170A9 (en) Compositions and methods for the treatment of immune related diseases
WO2004024097A9 (en) Compositions and methods for the treatment of immune related diseases
AU2003290548A1 (en) Prevention and treatment of synucleinopathic disease
WO2004060270A8 (en) Compositions and methods for the diagnosis and treatment of tumor
AU2003216482A1 (en) MSRAs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
WO2003057160A8 (en) Compositions and methods for the diagnosis and treatment of tumor
AU2003287443A1 (en) Compositions and methods for pain reduction
AU2003231252A1 (en) Methods and compositions for the treatment and prevention of intermittent claudication or alzheimer's disease
WO2005003154A8 (en) Compositions and methods for the diagnosis and treatment of tumor
PL371281A1 (en) Methods and compositions for the treatment of eye diseases
AU2003254146A1 (en) Methods for the treatment of parkinson's disease
AU2003237792A1 (en) Compositions and methods for the diagnosis and treatment of tumor
AU2003219160A1 (en) Methods and compositions for the treatment of cancer
EP1576109A3 (en) Methods and compositions for categorizing patients
AU2003248893A1 (en) Compositions and methods for the treatment of parkinson's disease and tardive dyskinesias
WO2004024076A8 (en) Novel compositions and methods for the treatment of immune related diseases
AU2003237657A1 (en) Means and methods for improved treatment using "setrones"
AU2003220026A1 (en) Methods and compositions for the treatment of ischemia
AU2003244455A1 (en) Piperidylcarboxamide derivatives and their use in the treatment of tachykinim-mediated diseases

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase